Raras
Buscar doenças, sintomas, genes...
Síndrome Aicardi-Goutieres
ORPHA:51CID-10 · G31.8CID-11 · 5C55.2DOENÇA RARA

A Síndrome de Aicardi-Goutières (AGS) é uma doença genética que afeta o cérebro e se manifesta aos poucos. Ela se caracteriza pela combinação de calcificação em regiões profundas do cérebro, alterações na substância branca cerebral e aumento de um tipo de glóbulo branco (linfócitos) no líquido que envolve o cérebro e a medula espinhal (LCR).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Síndrome de Aicardi-Goutières (AGS) é uma doença genética que afeta o cérebro e se manifesta aos poucos. Ela se caracteriza pela combinação de calcificação em regiões profundas do cérebro, alterações na substância branca cerebral e aumento de um tipo de glóbulo branco (linfócitos) no líquido que envolve o cérebro e a medula espinhal (LCR).

Publicações científicas
794 artigos
Último publicado: 2026 Apr 1
Medicamentos
1 registrados
BARICITINIB

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
BARICITINIB

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
10.0
Europe
Início
Antenatal
+ infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G31.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
39 sintomas
🩸
Sangue
13 sintomas
🫃
Digestivo
10 sintomas
❤️
Coração
10 sintomas
🫘
Rins
8 sintomas
👁️
Olhos
8 sintomas

+ 65 sintomas em outras categorias

Características mais comuns

90%prev.
Atraso global do desenvolvimento
Muito frequente (99-80%)
90%prev.
Hipertonia
Muito frequente (99-80%)
90%prev.
Espasticidade
Muito frequente (99-80%)
90%prev.
Anormalidades multifocais da substância branca cerebral
Muito frequente (99-80%)
90%prev.
Porencefalia
Muito frequente (99-80%)
90%prev.
Arrinencefalia
Muito frequente (99-80%)
183sintomas
Muito frequente (7)
Frequente (28)
Ocasional (28)
Muito raro (9)
Sem dados (111)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 183 características clínicas mais associadas, ordenadas por frequência.

Atraso global do desenvolvimentoGlobal developmental delay
Muito frequente (99-80%)90%
HipertoniaHypertonia
Muito frequente (99-80%)90%
EspasticidadeSpasticity
Muito frequente (99-80%)90%
Anormalidades multifocais da substância branca cerebralMultifocal cerebral white matter abnormalities
Muito frequente (99-80%)90%
PorencefaliaPorencephaly
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico794PubMed
Últimos 10 anos200publicações
Pico202571 papers
Linha do tempo
2026Hoje · 2026🧪 2015Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

9 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive.

RNASEH2CRibonuclease H2 subunit CDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Non catalytic subunit of RNase H2, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging-strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 3

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
70.5 TPM
Cérebro - Hemisfério cerebelar
68.3 TPM
Útero
67.2 TPM
Ovário
60.3 TPM
Cervix Endocervix
59.7 TPM
OUTRAS DOENÇAS (2)
Aicardi-Goutieres syndrome 3Aicardi-Goutieres syndrome
HGNC:24116UniProt:Q8TDP1
RNASEH2ARibonuclease H2 subunit ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of RNase HII, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging-strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 4

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
81.3 TPM
Testículo
49.8 TPM
Fibroblastos
44.5 TPM
Esôfago - Mucosa
24.3 TPM
Cervix Ectocervix
23.4 TPM
OUTRAS DOENÇAS (2)
Aicardi-Goutieres syndrome 4Aicardi-Goutieres syndrome
HGNC:18518UniProt:O75792
SAMHD1Deoxynucleoside triphosphate triphosphohydrolase SAMHD1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Protein that acts both as a host restriction factor involved in defense response to virus and as a regulator of DNA end resection at stalled replication forks (PubMed:19525956, PubMed:21613998, PubMed:21720370, PubMed:22056990, PubMed:23601106, PubMed:23602554, PubMed:24336198, PubMed:26294762, PubMed:26431200, PubMed:28229507, PubMed:28834754, PubMed:29670289). Has deoxynucleoside triphosphate (dNTPase) activity, which is required to restrict infection by viruses, such as HIV-1: dNTPase activit

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (2)
Interferon alpha/beta signalingNucleotide catabolism
MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 5

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
453.4 TPM
Esôfago - Muscular
225.4 TPM
Esôfago - Junção
209.5 TPM
Artéria coronária
194.4 TPM
Fallopian Tube
174.3 TPM
OUTRAS DOENÇAS (4)
chilblain lupus 2Aicardi-Goutieres syndrome 5familial chilblain lupusAicardi-Goutieres syndrome
HGNC:15925UniProt:Q9Y3Z3
LSM11U7 snRNA-associated Sm-like protein LSm11Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the U7 snRNP complex that is involved in the histone 3'-end pre-mRNA processing (PubMed:11574479, PubMed:16914750, PubMed:33230297). Increases U7 snRNA levels but not histone 3'-end pre-mRNA processing activity, when overexpressed (PubMed:11574479, PubMed:16914750). Required for cell cycle progression from G1 to S phases (By similarity). Binds specifically to the Sm-binding site of U7 snRNA (PubMed:11574479, PubMed:16914750)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
SLBP independent Processing of Histone Pre-mRNAsRNA Polymerase II Transcription TerminationSLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 8

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood. AGS8 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
19.5 TPM
Bladder
17.4 TPM
Cérebro - Hemisfério cerebelar
16.2 TPM
Cerebelo
12.9 TPM
Útero
12.7 TPM
OUTRAS DOENÇAS (2)
Aicardi-Goutieres syndrome 8Aicardi-Goutieres syndrome
HGNC:30860UniProt:P83369
IFIH1Interferon-induced helicase C domain-containing protein 1Disease-causing germline mutation(s) (gain of function) inTolerante
FUNÇÃO

Innate immune receptor which acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and pro-inflammatory cytokines (PubMed:28594402, PubMed:32169843, PubMed:33727702). Its ligands include mRNA lacking 2'-O-methylation at their 5' cap and long-dsRNA (>1 kb in length) (PubMed:22160685). Upon ligand binding it associates with mitochondria antiviral s

LOCALIZAÇÃO

CytoplasmNucleusMitochondrion

VIAS BIOLÓGICAS (10)
DDX58/IFIH1-mediated induction of interferon-alpha/betaNegative regulators of DDX58/IFIH1 signalingTRAF3-dependent IRF activation pathwaySARS-CoV-2 activates/modulates innate and adaptive immune responsesOvarian tumor domain proteases
MECANISMO DE DOENÇA

Type 1 diabetes mellitus 19

A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
87.0 TPM
Baço
15.9 TPM
Pulmão
13.4 TPM
Nervo tibial
11.7 TPM
Útero
11.1 TPM
OUTRAS DOENÇAS (5)
immunodeficiency 95Singleton-Merten syndrome 1Aicardi-Goutieres syndrome 7Singleton-Merten dysplasia
HGNC:18873UniProt:Q9BYX4
ADARDouble-stranded RNA-specific adenosine deaminaseDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:12618436, PubMed:7565688, PubMed:7972084). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins since the translational machinery read the inosine as a guanosine; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing seque

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nucleolus

VIAS BIOLÓGICAS (3)
Interferon alpha/beta signalingFormation of editosomes by ADAR proteinsC6 deamination of adenosine
MECANISMO DE DOENÇA

Dyschromatosis symmetrica hereditaria

An autosomal dominant pigmentary genodermatosis characterized by a mixture of hyperpigmented and hypopigmented macules distributed on the face and the dorsal parts of the hands and feet, that appear in infancy or early childhood.

OUTRAS DOENÇAS (4)
dyschromatosis symmetrica hereditariaAicardi-Goutieres syndrome 6Aicardi-Goutieres syndromefamilial infantile bilateral striatal necrosis
HGNC:225UniProt:P55265
RNU7-1Disease-causing germline mutation(s) inDesconhecido
LOCALIZAÇÃO

OUTRAS DOENÇAS (2)
Aicardi-Goutieres syndrome 9Aicardi-Goutieres syndrome
HGNC:34033
TREX1Three-prime repair exonuclease 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Major cellular 3'-to-5' DNA exonuclease which digests single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) with mismatched 3' termini (PubMed:10391904, PubMed:10393201, PubMed:17293595). Prevents cell-intrinsic initiation of autoimmunity (PubMed:10391904, PubMed:10393201, PubMed:17293595). Acts by metabolizing DNA fragments from endogenous retroelements, including L1, LTR and SINE elements (PubMed:10391904, PubMed:10393201, PubMed:17293595). Plays a key role in degradation of DNA fragment

LOCALIZAÇÃO

NucleusCytoplasm, cytosolEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
IRF3-mediated induction of type I IFNRegulation by TREX1
MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 1

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
80.6 TPM
Baço
45.2 TPM
Skin Sun Exposed Lower leg
42.6 TPM
Skin Not Sun Exposed Suprapubic
42.3 TPM
Pituitária
42.0 TPM
OUTRAS DOENÇAS (6)
retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestationschilblain lupus 1Aicardi-Goutieres syndrome 1Aicardi-Goutieres syndrome
HGNC:12269UniProt:Q9NSU2
RNASEH2BRibonuclease H2 subunit BDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Non catalytic subunit of RNase H2, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging-strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 2

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
17.9 TPM
Útero
14.7 TPM
Cervix Ectocervix
12.1 TPM
Fallopian Tube
12.0 TPM
Cólon sigmoide
11.6 TPM
OUTRAS DOENÇAS (2)
Aicardi-Goutieres syndrome 2Aicardi-Goutieres syndrome
HGNC:25671UniProt:Q5TBB1

Medicamentos e terapias

BARICITINIBPhase 2

Mecanismo: Tyrosine-protein kinase JAK2 inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

1,903 variantes patogênicas registradas no ClinVar.

🧬 RNASEH2C: NM_032193.4(RNASEH2C):c.*624C>T ()
🧬 RNASEH2C: NM_032193.4(RNASEH2C):c.173-20C>T ()
🧬 RNASEH2C: NM_032193.4(RNASEH2C):c.348+20T>G ()
🧬 RNASEH2C: NM_032193.4(RNASEH2C):c.374A>T (p.Asn125Ile) ()
🧬 RNASEH2C: NM_032193.4(RNASEH2C):c.299G>A (p.Arg100Gln) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 5,947 variantes classificadas pelo ClinVar.

297
1784
3866
Patogênica (5.0%)
VUS (30.0%)
Benigna (65.0%)
VARIANTES MAIS SIGNIFICATIVAS
RNASEH2A: NM_006397.3(RNASEH2A):c.637+1G>A [Likely pathogenic]
SAMHD1: NM_015474.4(SAMHD1):c.593G>A (p.Cys198Tyr) [Uncertain significance]
SAMHD1: NM_015474.4(SAMHD1):c.1787dup (p.Glu597fs) [Uncertain significance]
IFIH1: NM_022168.4(IFIH1):c.2575C>T (p.His859Tyr) [Uncertain significance]
ADAR: NM_001111.5(ADAR):c.707C>G (p.Ser236Cys) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 26
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 7 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Aicardi-Goutieres

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

7 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
575 papers (10 anos)
#1

Aberrant multicellular interferon signaling underlies Adar1 mutation-driven Aicardi-Goutières syndrome-like encephalopathy.

Cell reports2026 Mar 17

Adenosine-to-inosine RNA editing by ADAR1 prevents aberrant innate immunity activation by modifying endogenous double-stranded RNA. Mice carrying a left-handed double-stranded RNA (Z-RNA) binding-deficient mutation develop Aicardi-Goutières syndrome (AGS)-like encephalopathy, characterized by ventricular enlargement, gliosis, calcification, and white matter degeneration with a type I interferon (IFN) signature. However, the mechanisms underlying encephalopathy development remain unknown. Here, we show that pathology was most severe in periventricular regions where IFN-stimulated gene (ISG) expression was elevated and ependymal cells were lost, accompanied by higher IFN-α levels in cerebrospinal fluid than in sera. Blocking type I IFN signaling fully reversed these abnormalities, which was not achieved by deleting downstream PKR or ZBP1. Microglial elimination partially alleviated the encephalopathy without suppressing ISGs. In contrast, neuron- or astrocyte-specific ADAR1 dysfunction evoked robust ISG expression and recapitulated AGS-like encephalopathy, with astrocytic dysfunction causing particularly severe effects. These findings identify aberrant multicellular IFN signaling as the central driver of AGS-like encephalopathy.

#2

ADAR1 regulates dsRNA formation in nuclear and mitochondrial transcripts through editing-dependent and -independent mechanisms.

Cell reports2026 Mar 06

Endogenous (self) double-stranded RNAs (dsRNAs) in human cells can activate innate immune responses. ADAR1, an A-to-I editing enzyme of dsRNAs, suppresses aberrant immune activation by self-dsRNAs. However, how ADAR1 influences the cellular dsRNA landscape remains unclear. We show that human ADAR1 downregulates self-dsRNA abundance through editing-dependent and editing-independent mechanisms. We further conducted quantitative dsRNA sequencing on wild-type and ADAR1-deficient cells. dsRNAs are enriched in protein-coding mRNAs-especially those with repetitive elements and elongated 3' UTRs-and mitochondrial RNAs. ADAR1-regulated dsRNA transcripts consist of nuclear-encoded mRNAs and, unexpectedly, mitochondria-encoded RNAs rarely edited by ADAR1. Accordingly, dsRNAs accumulate to high levels within the mitochondria of ADAR1-deficient cells. Mass spectrometry and biochemical assays can detect ADAR1p150 in mitochondrial fractions. Notably, ADAR1 loss sensitizes cells to inflammation under mitochondrial stress (e.g., herniation and X-ray irradiation). Hence, we show that dsRNAs regulated by ADAR1 go beyond A-to-I edited transcripts and that ADAR1 can control mitochondrial dsRNAs.

#3

Pharmacological stabilization of hypoxia-inducible factor 1-α dampens the interferon response and promotes glycolysis in Aicardi-Goutières syndrome.

Nature communications2026 Mar 03

Aicardi-Goutières syndrome (AGS) is a genetic type I interferon (IFN)-mediated disease characterized by neurological involvement with onset in utero or in childhood. Here, we analyze peripheral blood samples from patients bearing AGS-causing mutations in ADAR1, RNASEH2B or SAMHD1 using single-cell transcriptomics and targeted metabolomics. Using machine-learning approaches and differential gene expression analysis, we identified a loss of transcription factor hypoxia induced factor 1 α (HIF-1α) expression and activity associated with features of a metabolic switch favoring oxidative phosphorylation and glutathione metabolism over glycolysis in monocytes and dendritic cells. Evidences of mitochondrial stress and accumulation of cytosolic double-stranded DNA and RNA were also found. The energy metabolic switch was confirmed at the metabolic level in primary peripheral blood mononuclear cells of AGS patients. Chemical stabilization of HIF-1α using a synthetic drug in in vitro cellular models of AGS, reversed the energy metabolic switch towards glycolysis, attenuated mitochondrial stress, and markedly reduced the IFN response and IP-10 production. We therefore propose that an energy metabolic switch contributes to chronic inflammation in AGS and that targeting this pathway might represent a potential therapeutic approach.

#4

Heterozygous ADAR mutant mice exhibit RNA sensing-dependent neuroinflammation and phenotypes associated with Aicardi-Goutières syndrome.

iScience2026 Feb 20

The ADAR G1007R mutation is frequently found in type six Aicardi-Goutières syndrome (AGS), a severe inflammatory encephalopathy in pediatric patients, and is distinct in having a phenotype in heterozygotes. To define the mechanisms underlying this disease, we developed an ADAR G1007 heterozygous mouse model that recapitulates the genetic and inflammatory features of individuals with ADAR G1007R AGS. These mice exhibited increased astrocytosis and microgliosis and interferon-stimulated gene (ISG) expression within deep brain areas. Additionally, brain inflammation was reversed by deletion of MDA5, which blocks cellular RNA sensing. Analysis of embryonic RNAs show the G1007R mutation also interrupts the splicing donor site in RNA transcripts, thereby altering ADAR1 RNA splicing and depleting the ADAR1 protein. Collectively, this study reports an animal model for AGS manifesting a heterozygous phenotype, reveals molecular defects associated with the ADAR G1007R mutation, and demonstrates that MDA5-dependent RNA sensing contributes to neuroinflammation.

#5

The Impact of RNA Polymerase III-Related Leukodystrophy on Nonaffected Family Members: A Qualitative Study.

Pediatric neurology2026 Mar

RNA polymerase III-related hypomyelinating leukodystrophy (POLR3-HLD) is a rare, neurodegenerative, brain white matter disorder characterized by hypomyelination, hypodontia, and hypogonadotropic hypogonadism. Due to the complex and progressive nature of this disorder, parents and siblings of patients face many potential challenges and stressors. We, therefore, sought to explore parents' and siblings' experiences to understand their specific needs and identify modifiable factors to limit familial burden and improve their quality of life. We conducted semistructured interviews with parents and siblings of patients with POLR3-HLD. Interview questions focused on the financial, emotional, and psychosocial impacts on parents, as well as siblings' relationship with their affected sibling and the psychosocial impacts they may have experienced. All interviews were recorded, transcribed, and analyzed using reflexive thematic analysis. Through the coding process, themes surrounding the impact on and experiences of parents and siblings were developed. Nineteen semistructured interviews with 24 parents and nine interviews with 9 siblings were completed between March and October 2023 and February and May 2024, respectively. Four themes from parent interviews included extensive caregiver burden, emotional and psychosocial challenges, the importance of parental self-health, and comfort in the leukodystrophy community. Three themes from sibling interviews included the spectrum of emotional impacts, limited knowledge about POLR3-HLD, and adapting to their sibling's needs. This study provides a comprehensive understanding of the family experience, identifying the common challenges and specific needs of parents and siblings, highlighting areas of improvement in the global care offered to this vulnerable patient population.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC379 artigos no totalmostrando 196

2026

Efficacy of JAK1/2 inhibitors in AGS genes-related interferonopathies: A multicenter retrospective observational study with treated vs untreated comparison.

Molecular genetics and metabolism
2026

Aberrant multicellular interferon signaling underlies Adar1 mutation-driven Aicardi-Goutières syndrome-like encephalopathy.

Cell reports
2026

Aicardi-Goutières Syndrome: Insights from a Middle Eastern Case Series.

AJNR. American journal of neuroradiology
2026

ADAR1 regulates dsRNA formation in nuclear and mitochondrial transcripts through editing-dependent and -independent mechanisms.

Cell reports
2026

Context-dependent effects of adaptive immunity on IFN-α-mediated neurotoxicity in Aicardi-Goutières syndrome.

Neurobiology of disease
2026

Pharmacological stabilization of hypoxia-inducible factor 1-α dampens the interferon response and promotes glycolysis in Aicardi-Goutières syndrome.

Nature communications
2026

Aicardi-Goutières Syndrome Type 3 with Persistent Hypertriglyceridemia: A Novel Association.

Indian journal of pediatrics
2026

Gut metabolites identified in cerebrospinal fluid of genetic interferonopathy support gut-brain endothelial dysfunction.

Clinical &amp; translational immunology
2026

Heterozygous ADAR mutant mice exhibit RNA sensing-dependent neuroinflammation and phenotypes associated with Aicardi-Goutières syndrome.

iScience
2026

A novel patient-Centered approach to clinical trial readiness in rare diseases: Application in Aicardi-Goutières Syndrome (AGS).

Molecular genetics and metabolism
2026

Aicardi-Goutières Syndrome caused by SAMHD1 mutation: Pathogenesis and Beyond.

Clinical immunology (Orlando, Fla.)
2026

Microglia replacement by ER-Hoxb8 conditionally immortalized macrophages provides insight into Aicardi-Goutières syndrome neuropathology.

eLife
2026

Basic Microglial Functions and How They Go Awry in Neurodegenerative Disease.

Annual review of pathology
2026

Monogenic and SLE-like disorders in the pediatric population: insights from a Northern Israel cohort.

Lupus
2026

The Impact of RNA Polymerase III-Related Leukodystrophy on Nonaffected Family Members: A Qualitative Study.

Pediatric neurology
2026

One mutation, divergent journeys: expanding the clinical spectrum of homozygous SAMHD1 deficiency in childhood.

Rheumatology (Oxford, England)
2025

The intersection of TREX1, cGAS, STING and the DNA damage theory of aging.

Frontiers in aging
2025

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses.

Signal transduction and targeted therapy
2025

Discovery of isoindoline-2(1H)-carboxamide STING inhibitors as anti-inflammatory agents.

Molecular diversity
2025

Generation of two iPSC lines from patients with Aicardi-Goutières syndrome carrying either biallelic ADAR1 mutations (PC138) or a heterozygous IFIH1 mutation (PC139).

Stem cell research
2025

Monogenic Mimics of Neuroinflammatory Phenotypes in Children and Young Adults: An Evolving Landscape.

Neurology. Genetics
2026

Triazole-based STING inhibitors.

Bioorganic &amp; medicinal chemistry
2026

Chronic interferon-alpha overexpression induces white matter damage and neurovascular abnormalities in a mouse model of Aicardi-Goutières syndrome.

Experimental neurology
2025

Discordant phenotype caused by TREX1 variant in siblings with Aicardi-Goutières syndrome.

Pediatric rheumatology online journal
2025

Update on new autoinflammatory disorders from the 2024 Pediatric Rheumatology European Society Congress.

Pediatric rheumatology online journal
2025

Newborn Screening of X-Linked Adrenoleukodystrophy in Italy: Clinical and Biochemical Outcomes from a 4-Year Pilot Study.

International journal of neonatal screening
2025

[Aicardi-Goutières syndrome with atypical presentation: RNASEH2B gene mutation in an infant without microcephaly or intracranial calcifications (a case report)].

The Pan African medical journal
2025

Mimickers of Systemic Lupus Erythematosus: Case Series and Literature Overview.

Journal of clinical medicine
2026

Discovery of a potent and orally bioavailable 3,3-dimethyl-2-oxoindoline STING inhibitor.

European journal of medicinal chemistry
2025

Myasthenia Gravis as a Manifestation of Aicardi-Goutières Syndrome Due to a SAMHD1 Variant Successfully Treated With Baricitinib.

Cureus
2025

Identification of Potential Therapeutic Agents for Type I Interferonopathy Using iPSC-Based Disease Modeling.

Journal of clinical immunology
2025

Nitrofuran-Based STING Inhibitors.

ACS omega
2026

Microgliosis and aberrant interferon response in Adar Mavs brain are rescued by PKR removal.

Brain : a journal of neurology
2025

Metformin Reduces Oxidative Damage in RNASEH2-Mutant Aicardi-Goutières Cells.

Genes
2025

Unravelling neurodegeneration with cerebral calcifications: Krabbe disease masquerading as Aicardi-Goutieres syndrome.

BMJ case reports
2025

Cystatin F-a key player in central nervous system disease.

Journal of neuroinflammation
2025

Clinical Characterization of a Multicenter International Cohort of Patients With Aicardi-Goutières Syndrome Homozygous for the RNASEH2B:p.Ala177Thr Variant: Early Clinical Markers of Disease Severity.

Pediatric neurology
2025

Familial Cases of Aicardi-Goutières Syndrome Presenting With Cutaneous Manifestations of Facial Lipodystrophy and Puffy Digits.

The Journal of dermatology
2025

Case Report: Heterozygous ADAR c.3019G>A pathogenic variant associated with variable neurological symptoms and incomplete penetrance in a four-generational family.

Frontiers in immunology
2025

Recurrent Hemorrhagic Stroke and Microcephaly in a Newborn with Aicardi-Goutières Syndrome Caused by a Homozygous Intronic RNASEH2B Variant.

Annals of clinical and laboratory science
2025

Dual pathology of parvovirus B19 infection and Aicardi-Goutières syndrome complicating non-immune hydrops fetalis.

BMJ case reports
2025

Yield of Whole Exome Sequencing in Children With Cryptogenic Cerebral Palsy.

Pediatric neurology
2025

ATAD3 duplications bridge mitochondrial diseases and Aicardi-Goutières syndrome.

Developmental medicine and child neurology
2025

ADAR1: Beyond Just an RNA Editor.

Annual review of cell and developmental biology
2025

Discovery of 3,4-dihydroisoquinoline-2(1H)-carboxamide STING inhibitors as anti-inflammatory agents.

European journal of medicinal chemistry
2025

Deep Brain Stimulation in a Child with Aicardi-Goutières Syndrome-7 (AGS7): A Case Report and Literature Review.

Movement disorders clinical practice
2025

KDM4B enhances immune surveillance via demethylating cGAS.

Cell death &amp; disease
2025

The ability of SAMHD1-deficient monocytes to trigger the Type I IFN response depends on cGAS and mitochondrial DNA.

The Journal of biological chemistry
2025

USP8-Governed MDA5 Homeostasis Promotes Innate Immunity and Autoimmunity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2025

Neuroglial Pathophysiology of Leukodystrophies.

Advances in neurobiology
2025

Moyamoya syndrome in a patient with Aicardi-Goutières syndrome associated with a SAMHD1 mutation: a case report.

Pediatric radiology
2025

Alternative cGAS signaling promotes herpes simplex encephalitis.

Proceedings of the National Academy of Sciences of the United States of America
2025

Talents Amidst Neurological Impairment; an Interesting Case of Aicardi-Goutières Syndrome.

Clinical case reports
2025

Experiences and Hope in Caregivers of Children With Aicardi Goutières Syndrome.

Journal of child neurology
2025

Aicardi-Goutières syndrome as a rare cause of neonatal intracranial calcifications.

Archives of disease in childhood. Fetal and neonatal edition
2025

French protocol for diagnosis and management of type 1 interferonopathies.

La Revue de medecine interne
2025

Exploration Into Lived Experiences of Multiple Sulfatase Deficiency-Affected Individuals and Their Families.

Journal of child neurology
2025

Repurposing oxiconazole to inhibit STING trafficking via OSBP and alleviate autoimmune pathology in Trex1-/- mice.

International immunopharmacology
2025

New Phenotypes Associated With Pathogenic RNASEH2B and SAMHD1 Variants.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
2025

The induction of type I interferonopathy in Trex1-P212fs mice is mediated by activation of the cGAS-STING pathway.

International journal of biological macromolecules
2025

The Rare Syndrome Aicardi-Goutières 4: A Case Report and Literature Review.

Developmental neurobiology
2025

Overlap Diagnostic Odyssey and Full Mouth Rehabilitation of a Juvenile Patient With IFIH1-Related Disorder: A Case of Aicardi-Goutières and Singleton Merten Syndromes Overlap.

Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
2025

Pharmacological evaluation of drug therapies in Aicardi-Goutières syndrome: insights from patient-derived neural stem cells.

Frontiers in pharmacology
2025

Tofacitinib treatment for psoriatic skin lesions associated with Aicardi-Goutières syndrome 7/Singleton-Merten syndrome 1.

Orphanet journal of rare diseases
2025

Delayed Diagnosis of Aicardi-Goutières Syndrome in a 10-Year-Old Female Child With TREX1 Mutation: A Case Report.

Cureus
2025

Petroselinic Acid from Apiaceae Family Plants Ameliorates Autoimmune Disorders Through Suppressing Cytosolic-Nucleic-Acid-Mediated Type I Interferon Signaling.

Biomolecules
2025

Neuroglia in leukodystrophies.

Handbook of clinical neurology
2025

Overlapping Aicardi-Goutières and Singleton-Merten syndromes with a heterozygous gain-of-function mutation in IFIH1 mimicking juvenile idiopathic arthritis.

Immunological medicine
2025

POLR3-Related Leukodystrophy: A Qualitative Study on Parents' Experiences With the Health Care System.

Pediatric neurology
2025

Biochemical profiling and structural basis of ADAR1-mediated RNA editing.

Molecular cell
2025

The DNase TREX1 is a substrate of the intramembrane protease SPP with implications for disease pathogenesis.

Cellular and molecular life sciences : CMLS
2025

Two rare mutations in homozygosity synergize to silence TREX1 in Aicardi-Goutières syndrome.

Frontiers in immunology
2025

Short-term efficacy of tofacitinib, a JAK inhibitor, in IFIH1-related Aicardi-Goutières syndrome.

European journal of medical genetics
2025

Autoinflammatory encephalopathy due to PTPN1 haploinsufficiency: a case series.

The Lancet. Neurology
2025

EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO).

Annals of the rheumatic diseases
2025

[Aicardi-Goutieres syndrome type 6 associated with a compound heterozygous variant in ADAR: a first case report in the Russian population].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

A 33-year diagnostic odyssey in an Ashkenazi Jewish patient with Aicardi-Goutières syndrome.

The journal of allergy and clinical immunology. Global
2025

The c.529G>A (p.Ala177Thr) RNASEH2B Gene Pathogenic Variant as a First-Line Genetic Test for Aicardi-Goutières Syndrome: A Case Series of Four Moroccan Families.

American journal of medical genetics. Part A
2025

Increased interferon I signaling, DNA damage response and evidence of T-cell exhaustion in a patient with combined interferonopathy (Aicardi-Goutières Syndrome, AGS) and cohesinopathy (Cornelia de Lange Syndrome, CdLS).

Pediatric rheumatology online journal
2025

Mouse models for understanding physiological functions of ADARs.

Methods in enzymology
2024

Corrigendum: A zebrafish model of Ifih1-driven Aicardi-Goutières syndrome reproduces the interferon signature and the exacerbated inflammation of patients.

Frontiers in immunology
2025

Reverse transcriptase inhibitors in Aicardi-Goutières syndrome: Design and regulatory challenges in clinical trials for rare disease.

Developmental medicine and child neurology
2025

A Wonderful Journey: The Diverse Roles of Adenosine Deaminase Action on RNA 1 (ADAR1) in Central Nervous System Diseases.

CNS neuroscience &amp; therapeutics
2025

Baricitinib Treatment in RNU7-1-Associated Aicardi-Goutières Syndrome in a South African Child: A Case Report.

American journal of medical genetics. Part A
2025

Bilateral striatal necrosis in a case with ADAR1-related Aicardi Goutières Syndrome.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2024

Aicardi-Goutières syndrome type 6: report of ADAR variant and clinical outcome after ruxolitinib treatment in the neonatal period.

Pediatric rheumatology online journal
2025

Reverse transcriptase inhibitors in Aicardi-Goutières syndrome: A crossover clinical trial.

Developmental medicine and child neurology
2024

Exploring emerging JAK inhibitors in the treatment of Aicardi-Goutières syndrome.

Expert opinion on emerging drugs
2025

Clinico-Radiological Mimics and Outcome of Intrauterine TORCH Infection and Aicardi-Goutieres Syndrome; Pseudo-TORCH from a Tertiary Care Centre in South India.

Indian journal of pediatrics
2025

Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus.

Nature reviews. Rheumatology
2024

The prototypical interferonopathy: Aicardi-Goutières syndrome from bedside to bench.

Immunological reviews
2025

An overview of genetic mutations in Aicardi-Goutières syndrome in Iranian population.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2024

Whole exome sequencing in patients with childhood-onset systemic lupus erythematosus: Results from a Croatian national study.

Scandinavian journal of immunology
2024

Neurophenotype and genetic analysis of children with Aicardi-Goutières syndrome in China.

Pediatric investigation
2024

Systemic complications of Aicardi Goutières syndrome using real-world data.

Molecular genetics and metabolism
2024

Childhood-inherited white matter disorders with calcification.

Handbook of clinical neurology
2024

cGAS activation in classical dendritic cells causes autoimmunity in TREX1-deficient mice.

Proceedings of the National Academy of Sciences of the United States of America
2024

Second generation lethality in RNAseH2a knockout zebrafish.

Nucleic acids research
2024

A case of severe Aicardi-Goutières syndrome with a homozygous RNASEH2B intronic variant.

Human genome variation
2024

An ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA inhibits PKR activation.

Cell reports
2024

Interferonopathies: From concept to clinical practice.

Best practice &amp; research. Clinical rheumatology
2025

Successful Electroconvulsive Therapy in Aicardi-Goutières Syndrome Presenting Psychiatric Symptoms: An Unprecedented Clinical Case.

The journal of ECT
2024

Children With Type I Interferonopathy: Commonalities and Diversities in a Large Patient Cohort.

The Journal of rheumatology
2024

Aicardi-Goutières Syndrome Type 1: A Novel Missense Variant and Review of the Mutational Spectrum.

Iranian journal of child neurology
2024

Monogenic interferon-mediated diseases: novel phenotype and genotype characteristics from a Saudi population.

Clinical and experimental rheumatology
2024

De novo variants in immune regulatory genes in Down syndrome regression disorder.

Journal of neurology
2024

IFN-signaling gene expression as a diagnostic biomarker for monogenic interferonopathies.

JCI insight
2024

The brain microvasculature is a primary mediator of interferon-α neurotoxicity in human cerebral interferonopathies.

Immunity
2024

Distinct features of ribonucleotides within genomic DNA in Aicardi-Goutières syndrome ortholog mutants of Saccharomyces cerevisiae.

iScience
2024

Nonverbal Cognitive Skills in Children With Aicardi Goutières Syndrome.

Neurology
2024

Soluble form of the MDA5 protein in human sera.

Heliyon
2024

T-Rex escaped from the cytosolic park: Re-thinking the impact of TREX1 exonuclease deficiencies on genomic stability.

BioEssays : news and reviews in molecular, cellular and developmental biology
2024

Mutations in the non-catalytic polyproline motif destabilize TREX1 and amplify cGAS-STING signaling.

Human molecular genetics
2024

The Sixth Sense: Self-nucleic acid sensing in the brain.

Advances in immunology
2024

Neurological Findings and a Brief Review of the Current Literature in a Severe Case of Aicardi-Goutières Syndrome Due to an IFIH1 Mutation.

Neuropediatrics
2024

Indomethacin restrains cytoplasmic nucleic acid-stimulated immune responses by inhibiting the nuclear translocation of IRF3.

Journal of molecular cell biology
2024

Pseudo-catatonia and Acral Degos-like Lesions: An Atypical Form of the Aicardi-Goutières Syndrome.

Actas dermo-sifiliograficas
2024

Characterization of Fine Motor and Visual Motor Skills in Aicardi-Goutières Syndrome.

Journal of child neurology
2024

Corrigendum: Newborn screening for X-linked adrenoleukodystrophy in Italy: diagnostic algorithm and disease monitoring.

Frontiers in neurology
2024

NOTCH1-Related Leukoencephalopathy: A Novel Variant and Literature Review.

International journal of molecular sciences
2024

Preimplantation genetic testing for monogenic disorders (PGT-M) offers an alternative strategy to prevent children from being born with hereditary neurological diseases or metabolic diseases dominated by nervous system phenotypes: a retrospective study.

Journal of assisted reproduction and genetics
2024

Intracranial calcifications simulating Aicardi-Goutières syndrome in PARS2-related mitochondrial disease.

American journal of medical genetics. Part A
2024

Nucleotide metabolism, leukodystrophies, and CNS pathology.

Journal of inherited metabolic disease
2024

Leukodystrophy Imaging: Insights for Diagnostic Dilemmas.

Medical sciences (Basel, Switzerland)
2024

Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières Syndrome.

Journal of clinical immunology
2024

Systematic analysis of genotype-phenotype variability in siblings with Aicardi Goutières Syndrome (AGS).

Molecular genetics and metabolism
2024

SAMHD1 dysfunction induces IL-34 expression via NF-κB p65 in neuronal SH-SY5Y cells.

Molecular immunology
2024

Interferon-α receptor antisense oligonucleotides reduce neuroinflammation and neuropathology in a mouse model of cerebral interferonopathy.

The Journal of clinical investigation
2024

Characterization of the molecular dysfunctions occurring in Aicardi-Goutières syndrome patients with mutations in ADAR1.

Genes &amp; diseases
2024

Progress in leukodystrophies with zebrafish.

Development, growth &amp; differentiation
2024

LicochalconeB inhibits cGAS-STING signaling pathway and prevents autoimmunity diseases.

International immunopharmacology
2024

Impact of Disease-Associated Mutations on the Deaminase Activity of ADAR1.

Biochemistry
2024

Generation of three induced pluripotent stem cell lines from individuals with Aicardi-Goutières syndrome caused by a c.3019G>A (p.G1007R) autosomal dominant pathogenic variant in ADAR1.

Stem cell research
2024

TREX-1 related Aicardi-Goutières syndrome improved by Janus kinase inhibitor.

American journal of medical genetics. Part A
2024

TREX1 is required for microglial cholesterol homeostasis and oligodendrocyte terminal differentiation in human neural assembloids.

Molecular psychiatry
2023

A zebrafish model of Ifih1-driven Aicardi-Goutières syndrome reproduces the interferon signature and the exacerbated inflammation of patients.

Frontiers in immunology
2024

SAMHD1 compound heterozygous rare variants associated with moyamoya and mitral valve disease in the absence of other features of Aicardi-Goutières syndrome.

American journal of medical genetics. Part A
2023

Aicardi-Goutières Syndrome with Congenital Glaucoma Caused by Novel TREX1 Mutation.

Journal of personalized medicine
2024

STING signaling in the brain: Molecular threats, signaling activities, and therapeutic challenges.

Neuron
2024

Aicardi-Goutières Syndrome (AGS) Presenting with Psoriasis.

Indian journal of pediatrics
2023

Distinct features of ribonucleotides within genomic DNA in Aicardi-Goutières syndrome (AGS)-ortholog mutants of Saccharomyces cerevisiae.

bioRxiv : the preprint server for biology
2023

Long 3'UTRs predispose neurons to inflammation by promoting immunostimulatory double-stranded RNA formation.

Science immunology
2024

Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutières syndrome.

Journal of neurology
2023

Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study.

Pediatric rheumatology online journal
2023

Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib.

Pediatric rheumatology online journal
2023

Type I Interferonopathies: A Clinical Review.

Rheumatic diseases clinics of North America
2023

Synthetic lethal mutants in Escherichia coli define pathways necessary for survival with RNase H deficiency.

Journal of bacteriology
2024

Dyschromatosis symmetrica hereditaria: A clue to early diagnosis of Aicardi-Goutières syndrome.

Pediatric dermatology
2024

Novel insights into double-stranded RNA-mediated immunopathology.

Nature reviews. Immunology
2024

Multi-dimensional Insight into the Coexistence of Pathogenic Genes for ADAR1 and TSC2: Careful Consideration is Essential for Interpretation of ADAR1 Variants.

Biochemical genetics
2023

Patients on the Transplant Waiting List Have Anti-Swine Leukocyte Antigen Class I Antibodies.

ImmunoHorizons
2023

Development of LB244, an Irreversible STING Antagonist.

Journal of the American Chemical Society
2023

Inhibitors of Stimulator of Interferon Genes from 2019 to July 2022: An Overview of the Structure and Bioactivity.

Current drug targets
2024

LINE-1: an emerging initiator of cGAS-STING signalling and inflammation that is dysregulated in disease.

Biochemistry and cell biology = Biochimie et biologie cellulaire
2023

Subacute Partially Reversible Leukoencephalopathy Expands the Aicardi-Goutières Syndrome Phenotype.

Brain sciences
2023

Biochemical functions and structure of Caenorhabditis elegans ZK177.8 protein: Aicardi-Goutières syndrome SAMHD1 dNTPase ortholog.

The Journal of biological chemistry
2023

Treatment response to Janus kinase inhibitor in a child affected by Aicardi-Goutières syndrome.

Clinical case reports
2023

Aicardi-Goutières syndrome: A monogenic type I interferonopathy.

Scandinavian journal of immunology
2023

Exploration of Gross Motor Function in Aicardi-Goutières Syndrome.

Journal of child neurology
2023

In Silico Characterization of RNASEH2A Pathogenic Variants and Identification of Novel Splice Site Donor Variant c.549+1G>T in Indian Population.

Cureus
2023

ADAR1 Zα domain P195A mutation activates the MDA5-dependent RNA-sensing signaling pathway in brain without decreasing overall RNA editing.

Cell reports
2023

Juvenile Dermatomyositis and Infantile Cerebral Palsy: Aicardi-Gouteres Syndrome, Type 5, with a Novel Mutation in SAMHD1-A Case Report.

Biomedicines
2023

Aicardi-Goutières syndrome presenting with pneumocystis jirovecii pneumonia.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2023

Rosmarinic acid ameliorates autoimmune responses through suppression of intracellular nucleic acid-mediated type I interferon expression.

Biochemical and biophysical research communications
2023

[Establishment of induced pluripotent stem cell model of Aicardi-Goutières Syndrome mutated in TREX1].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
2023

IFIH1 and DDX58 gene variants in pediatric rheumatic diseases.

World journal of clinical pediatrics
2023

A case report of two Moroccan patients with hereditary neurological disorders and molecular modeling study on the S72L de novo PMP22 variant.

Revue neurologique
2023

Construction and characterization of ribonuclease H2 C subunit-knockout NIH3T3 cells.

Bioscience, biotechnology, and biochemistry
2023

Generation of a new Adar1p150 -/- mouse demonstrates isoform-specific roles in embryonic development and adult homeostasis.

RNA (New York, N.Y.)
2023

Preimplantation genetic testing for Aicardi-Goutières syndrome induced by novel compound heterozygous mutations of TREX1: an unaffected live birth.

Molecular cytogenetics
2023

Aicardi-Goutières syndrome and dyschromatosis symmetrica hereditaria due to compound heterozygous mutation of ADAR1, presentation of two cases.

International journal of dermatology
2023

JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.

Journal of clinical immunology
2023

Aicardi-Goutières syndrome type 7 in a Chinese child: A case report.

World journal of clinical cases
2023

Meloxicam inhibits STING phosphorylation and alleviates intracellular DNA-mediated autoimmune responses.

Cell &amp; bioscience
2023

RNASEH2C c.194G>A is a Chinese-specific founder mutation in three unrelated patients with Aicardi-Goutières syndrome 3.

Clinical genetics
2023

Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).

Pediatric rheumatology online journal
2023

Aicardi-Goutieres Syndrome Type-1 without Intracranial Calcifications.

Indian journal of pediatrics
2023

The ADAR1 editome reveals drivers of editing-specificity for ADAR1-isoforms.

Nucleic acids research
2023

Comparison between D-loop methylation and mtDNA copy number in patients with Aicardi-Goutières Syndrome.

Frontiers in endocrinology
2023

The phenotype of the most common human ADAR1p150 Zα mutation P193A in mice is partially penetrant.

EMBO reports
2023

Altered DNA methylation and gene expression predict disease severity in patients with Aicardi-Goutières syndrome.

Clinical immunology (Orlando, Fla.)
2023

Characterization of a mutant samhd1 zebrafish model implicates dysregulation of cholesterol biosynthesis in Aicardi-Goutières syndrome.

Frontiers in immunology
2023

SAMHD1 restricts the deoxyguanosine triphosphate pool contributing to telomere stability in telomerase-positive cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2023

Adar-associated Aicardi Goutières syndrome in a child with bilateral striatal necrosis and recurrent episodes of transaminitis.

BMJ case reports
2023

Differential Structural Features of Two Mutant ADAR1p150 Zα Domains Associated with Aicardi-Goutières Syndrome.

Journal of molecular biology
2023

Breaking down the cellular responses to type I interferon neurotoxicity in the brain.

Frontiers in immunology
2023

A case of Aicardi-Goutières syndrome caused by TREX1 gene mutation.

BMC pregnancy and childbirth
2023

Molecular characterization of an intronic RNASEH2B variant in a patient with Aicardi-Goutières syndrome.

European journal of medical genetics
2023

Early arteriopathy in Aicardi-Goutières syndrome 5. Case report and review of literature.

The neuroradiology journal
2022

Newborn screening for X-linked adrenoleukodystrophy in Italy: Diagnostic algorithm and disease monitoring.

Frontiers in neurology
2022

Case report: Pneumocystis jirovecii pneumonia in a severe case of Aicardi-Goutières syndrome with an IFIH1 gain-of-function mutation mimicking combined immunodeficiency.

Frontiers in immunology
2023

Clinical spectrum and currently available treatment of type I interferonopathy Aicardi-Goutières syndrome.

World journal of pediatrics : WJP
2023

Aicardi-Goutières syndrome: The need for clinical vigilance in fetuses with sonographic features of congenital infection.

European journal of obstetrics, gynecology, and reproductive biology
2023

[Clinical report and genetic analysis of a child with Aicardi-Goutières syndrome type 3 due to compound heterozygous variants of RNASEH2C gene].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2022

Aicardi-Goutières syndrome (AGS): recurrent fetal cardiomyopathy and pseudo-TORCH syndrome.

BMJ case reports
2022

Early recognition of patients with leukodystrophies.

Current problems in pediatric and adolescent health care
Ver todos os 379 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Aicardi-Goutieres.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Aicardi-Goutieres

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Aberrant multicellular interferon signaling underlies Adar1 mutation-driven Aicardi-Gouti&#xe8;res syndrome-like encephalopathy.
    Cell reports· 2026· PMID 41855203mais citado
  2. ADAR1 regulates dsRNA formation in nuclear and mitochondrial transcripts through editing-dependent and -independent mechanisms.
    Cell reports· 2026· PMID 41800619mais citado
  3. Pharmacological stabilization of hypoxia-inducible factor 1-&#x3b1; dampens the interferon response and promotes glycolysis in Aicardi-Gouti&#xe8;res syndrome.
    Nature communications· 2026· PMID 41776196mais citado
  4. Heterozygous ADAR mutant mice exhibit RNA sensing-dependent neuroinflammation and phenotypes associated with Aicardi-Gouti&#xe8;res syndrome.
    iScience· 2026· PMID 41704749mais citado
  5. The Impact of RNA Polymerase III-Related Leukodystrophy on Nonaffected Family Members: A Qualitative Study.
    Pediatric neurology· 2026· PMID 41518854mais citado
  6. Spastic Hip Dislocation in a Child With Aicardi-Goutières Syndrome: A Case Report.
    JBJS Case Connect· 2026· PMID 41985016recente
  7. PTPN1 -related autoinflammation is a common cause of Aicardi-Goutières Syndrome with reduced penetrance.
    medRxiv· 2026· PMID 41959779recente
  8. Aicardi-Goutières Syndrome Type 6: Case Report and Structural Prediction Supporting a Dominant-Negative Effect of the ADAR1 c.3019G>A Variant.
    Clin Case Rep· 2026· PMID 41948752recente
  9. First case of TREX1 mutation-driven retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations coexisting with lupus nephritis: a case report and mechanistic discussion.
    Front Immunol· 2026· PMID 41939917recente
  10. Efficacy of JAK1/2 inhibitors in AGS genes-related interferonopathies: A multicenter retrospective observational study with treated vs untreated comparison.
    Mol Genet Metab· 2026· PMID 41871482recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:51(Orphanet)
  2. MONDO:0018866(MONDO)
  3. GARD:575(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q403453(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Aicardi-Goutieres
Compêndio · Raras BR

Síndrome Aicardi-Goutieres

ORPHA:51 · MONDO:0018866
Prevalência
Unknown
Herança
Autosomal dominant, Autosomal recessive
CID-10
G31.8 · Outras doenças degenerativas especificadas do sistema nervoso
CID-11
Medicamentos
1 registrados
Início
Antenatal, Infancy, Neonatal
Prevalência
10.0 (Europe)
MedGen
UMLS
C0393591
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades